“Italian HIV Vaccine Trial Ready to Begin”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

Reuters Health Information Services (www.reutershealth.com) (06/05/03); Lorenzi, Rossella

Valeria Fiorelli of Italy's National Health Institute Laboratory says human trials for an experimental vaccine to prevent and treat HIV will begin soon, pending regulatory approval. The vaccine works by blocking HIV's transcriptional activation protein, which is released soon after infection. Animal testing produced an effectiveness rate of about 71 percent without toxicity complications. HIV-negative adult volunteers will participate in the HIV prevention vaccination trial, while patients infected with HIV-1, who have mild immunodeficiency, will be involved in the treatment trial.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.